Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme

Amanda Tivnan, Zaitun Zakaria, Caitrín O'Leary, Donat Kögel, Jenny L. Pokorny, Jann N Sarkaria, Jochen H M Prehn

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Glioblastoma multiforme (GBM) is a highly aggressive brain cancer with extremely poor prognostic outcome despite intensive treatment. All chemotherapeutic agents currently used have no greater than 30-40% response rate, many fall into the range of 10-20%, with delivery across the blood brain barrier (BBB) or chemoresistance contributing to the extremely poor outcomes despite treatment. Increased expression of the multidrug resistance protein 1(MRP1) in high grade glioma, and it's role in BBB active transport, highlights this member of the ABC transporter family as a target for improving drug responses in GBM. In this study we show that small molecule inhibitors and gene silencing of MRP1 had a significant effect on GBM cell response to temozolomide (150μM), vincristine (100nM) and etoposide (2μM). Pre-treatment with Reversan (inhibitor of MRP1 and P-glycoprotein) led to a significantly improved response to cell death in the presence of all three chemotherapeutics, in both primary and recurrent GBM cells. The presence of MK571 (inhibitor of MRP1 and Multidrug resistance protein 4 (MRP4) led to an enhanced effect of vincristine and etoposide in reducing cell viability over a 72 hour period. Specific MRP1 inhibition led to a significant increase in vincristine and etoposide induced cell death in all three cell lines assessed. Treatment with MK571, or specific MRP1 knockdown, did not have any effect on temozolomide drug response in these cells. These findings have significant implications in providing researchers an opportunity to improve currently used chemotherapeutics for the initial treatment of primary GBM, and improved treatment for recurrent GBM patients.

Original languageEnglish (US)
Article number218
JournalFrontiers in Neuroscience
Volume9
Issue numberMAY
DOIs
StatePublished - 2015

Fingerprint

P-Glycoprotein
Glioblastoma
Drug Therapy
temozolomide
Pharmaceutical Preparations
Vincristine
Etoposide
Blood-Brain Barrier
Cell Death
P-Glycoproteins
Therapeutics
ATP-Binding Cassette Transporters
Active Biological Transport
Gene Silencing
Brain Neoplasms
Glioma
Cell Survival
Research Personnel
Cell Line

Keywords

  • Chemoresistance
  • Glioblastoma
  • Multidrug resistance protein 1
  • siRNA

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme. / Tivnan, Amanda; Zakaria, Zaitun; O'Leary, Caitrín; Kögel, Donat; Pokorny, Jenny L.; Sarkaria, Jann N; Prehn, Jochen H M.

In: Frontiers in Neuroscience, Vol. 9, No. MAY, 218, 2015.

Research output: Contribution to journalArticle

Tivnan, Amanda ; Zakaria, Zaitun ; O'Leary, Caitrín ; Kögel, Donat ; Pokorny, Jenny L. ; Sarkaria, Jann N ; Prehn, Jochen H M. / Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme. In: Frontiers in Neuroscience. 2015 ; Vol. 9, No. MAY.
@article{431d18d5d4b14cb08be21e0fffcb95ca,
title = "Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme",
abstract = "Glioblastoma multiforme (GBM) is a highly aggressive brain cancer with extremely poor prognostic outcome despite intensive treatment. All chemotherapeutic agents currently used have no greater than 30-40{\%} response rate, many fall into the range of 10-20{\%}, with delivery across the blood brain barrier (BBB) or chemoresistance contributing to the extremely poor outcomes despite treatment. Increased expression of the multidrug resistance protein 1(MRP1) in high grade glioma, and it's role in BBB active transport, highlights this member of the ABC transporter family as a target for improving drug responses in GBM. In this study we show that small molecule inhibitors and gene silencing of MRP1 had a significant effect on GBM cell response to temozolomide (150μM), vincristine (100nM) and etoposide (2μM). Pre-treatment with Reversan (inhibitor of MRP1 and P-glycoprotein) led to a significantly improved response to cell death in the presence of all three chemotherapeutics, in both primary and recurrent GBM cells. The presence of MK571 (inhibitor of MRP1 and Multidrug resistance protein 4 (MRP4) led to an enhanced effect of vincristine and etoposide in reducing cell viability over a 72 hour period. Specific MRP1 inhibition led to a significant increase in vincristine and etoposide induced cell death in all three cell lines assessed. Treatment with MK571, or specific MRP1 knockdown, did not have any effect on temozolomide drug response in these cells. These findings have significant implications in providing researchers an opportunity to improve currently used chemotherapeutics for the initial treatment of primary GBM, and improved treatment for recurrent GBM patients.",
keywords = "Chemoresistance, Glioblastoma, Multidrug resistance protein 1, siRNA",
author = "Amanda Tivnan and Zaitun Zakaria and Caitr{\'i}n O'Leary and Donat K{\"o}gel and Pokorny, {Jenny L.} and Sarkaria, {Jann N} and Prehn, {Jochen H M}",
year = "2015",
doi = "10.3389/fnins.2015.00218",
language = "English (US)",
volume = "9",
journal = "Frontiers in Neuroscience",
issn = "1662-4548",
publisher = "Frontiers Research Foundation",
number = "MAY",

}

TY - JOUR

T1 - Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme

AU - Tivnan, Amanda

AU - Zakaria, Zaitun

AU - O'Leary, Caitrín

AU - Kögel, Donat

AU - Pokorny, Jenny L.

AU - Sarkaria, Jann N

AU - Prehn, Jochen H M

PY - 2015

Y1 - 2015

N2 - Glioblastoma multiforme (GBM) is a highly aggressive brain cancer with extremely poor prognostic outcome despite intensive treatment. All chemotherapeutic agents currently used have no greater than 30-40% response rate, many fall into the range of 10-20%, with delivery across the blood brain barrier (BBB) or chemoresistance contributing to the extremely poor outcomes despite treatment. Increased expression of the multidrug resistance protein 1(MRP1) in high grade glioma, and it's role in BBB active transport, highlights this member of the ABC transporter family as a target for improving drug responses in GBM. In this study we show that small molecule inhibitors and gene silencing of MRP1 had a significant effect on GBM cell response to temozolomide (150μM), vincristine (100nM) and etoposide (2μM). Pre-treatment with Reversan (inhibitor of MRP1 and P-glycoprotein) led to a significantly improved response to cell death in the presence of all three chemotherapeutics, in both primary and recurrent GBM cells. The presence of MK571 (inhibitor of MRP1 and Multidrug resistance protein 4 (MRP4) led to an enhanced effect of vincristine and etoposide in reducing cell viability over a 72 hour period. Specific MRP1 inhibition led to a significant increase in vincristine and etoposide induced cell death in all three cell lines assessed. Treatment with MK571, or specific MRP1 knockdown, did not have any effect on temozolomide drug response in these cells. These findings have significant implications in providing researchers an opportunity to improve currently used chemotherapeutics for the initial treatment of primary GBM, and improved treatment for recurrent GBM patients.

AB - Glioblastoma multiforme (GBM) is a highly aggressive brain cancer with extremely poor prognostic outcome despite intensive treatment. All chemotherapeutic agents currently used have no greater than 30-40% response rate, many fall into the range of 10-20%, with delivery across the blood brain barrier (BBB) or chemoresistance contributing to the extremely poor outcomes despite treatment. Increased expression of the multidrug resistance protein 1(MRP1) in high grade glioma, and it's role in BBB active transport, highlights this member of the ABC transporter family as a target for improving drug responses in GBM. In this study we show that small molecule inhibitors and gene silencing of MRP1 had a significant effect on GBM cell response to temozolomide (150μM), vincristine (100nM) and etoposide (2μM). Pre-treatment with Reversan (inhibitor of MRP1 and P-glycoprotein) led to a significantly improved response to cell death in the presence of all three chemotherapeutics, in both primary and recurrent GBM cells. The presence of MK571 (inhibitor of MRP1 and Multidrug resistance protein 4 (MRP4) led to an enhanced effect of vincristine and etoposide in reducing cell viability over a 72 hour period. Specific MRP1 inhibition led to a significant increase in vincristine and etoposide induced cell death in all three cell lines assessed. Treatment with MK571, or specific MRP1 knockdown, did not have any effect on temozolomide drug response in these cells. These findings have significant implications in providing researchers an opportunity to improve currently used chemotherapeutics for the initial treatment of primary GBM, and improved treatment for recurrent GBM patients.

KW - Chemoresistance

KW - Glioblastoma

KW - Multidrug resistance protein 1

KW - siRNA

UR - http://www.scopus.com/inward/record.url?scp=84931259785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931259785&partnerID=8YFLogxK

U2 - 10.3389/fnins.2015.00218

DO - 10.3389/fnins.2015.00218

M3 - Article

AN - SCOPUS:84931259785

VL - 9

JO - Frontiers in Neuroscience

JF - Frontiers in Neuroscience

SN - 1662-4548

IS - MAY

M1 - 218

ER -